Browse RELA

Summary
SymbolRELA
Namev-rel avian reticuloendotheliosis viral oncogene homolog A
Aliases NFKB3; nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; NF-kappa-B p65delta3; NF-kappa- ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus. Cytoplasm. Note=Colocalized with DDX1 in the nucleus upon TNF-alpha induction (By similarity). Nuclear, but also found in the cytoplasm in an inactive form complexed to an inhibitor (I-kappa-B). Colocalizes with GFI1 in the nucleus after LPS stimulation.
Domain PF16179 Rel homology dimerisation domain
PF00554 Rel homology DNA-binding domain
Function

NF-kappa-B is a pleiotropic transcription factor present in almost all cell types and is the endpoint of a series of signal transduction events that are initiated by a vast array of stimuli related to many biological processes such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52 and the heterodimeric p65-p50 complex appears to be most abundant one. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric p65-p50 and p65-c-Rel complexes are transcriptional activators. The NF-kappa-B p65-p65 complex appears to be involved in invasin-mediated activation of IL-8 expression. The inhibitory effect of I-kappa-B upon NF-kappa-B the cytoplasm is exerted primarily through the interaction with p65. p65 shows a weak DNA-binding site which could contribute directly to DNA binding in the NF-kappa-B complex. Associates with chromatin at the NF-kappa-B promoter region via association with DDX1. Essential for cytokine gene expression in T-cells (PubMed:15790681).

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001101 response to acid chemical
GO:0001501 skeletal system development
GO:0001819 positive regulation of cytokine production
GO:0001889 liver development
GO:0001942 hair follicle development
GO:0002062 chondrocyte differentiation
GO:0002218 activation of innate immune response
GO:0002220 innate immune response activating cell surface receptor signaling pathway
GO:0002221 pattern recognition receptor signaling pathway
GO:0002223 stimulatory C-type lectin receptor signaling pathway
GO:0002237 response to molecule of bacterial origin
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002753 cytoplasmic pattern recognition receptor signaling pathway
GO:0002757 immune response-activating signal transduction
GO:0002758 innate immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006081 cellular aldehyde metabolic process
GO:0006117 acetaldehyde metabolic process
GO:0006968 cellular defense response
GO:0006979 response to oxidative stress
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007422 peripheral nervous system development
GO:0007568 aging
GO:0007584 response to nutrient
GO:0008286 insulin receptor signaling pathway
GO:0008544 epidermis development
GO:0009314 response to radiation
GO:0009411 response to UV
GO:0009416 response to light stimulus
GO:0009612 response to mechanical stimulus
GO:0009615 response to virus
GO:0009894 regulation of catabolic process
GO:0009895 negative regulation of catabolic process
GO:0009991 response to extracellular stimulus
GO:0010001 glial cell differentiation
GO:0010035 response to inorganic substance
GO:0010224 response to UV-B
GO:0010586 miRNA metabolic process
GO:0010720 positive regulation of cell development
GO:0014013 regulation of gliogenesis
GO:0014015 positive regulation of gliogenesis
GO:0014037 Schwann cell differentiation
GO:0014038 regulation of Schwann cell differentiation
GO:0014040 positive regulation of Schwann cell differentiation
GO:0014072 response to isoquinoline alkaloid
GO:0014074 response to purine-containing compound
GO:0022404 molting cycle process
GO:0022405 hair cycle process
GO:0030522 intracellular receptor signaling pathway
GO:0031293 membrane protein intracellular domain proteolysis
GO:0031349 positive regulation of defense response
GO:0031667 response to nutrient levels
GO:0032330 regulation of chondrocyte differentiation
GO:0032332 positive regulation of chondrocyte differentiation
GO:0032479 regulation of type I interferon production
GO:0032481 positive regulation of type I interferon production
GO:0032495 response to muramyl dipeptide
GO:0032496 response to lipopolysaccharide
GO:0032570 response to progesterone
GO:0032606 type I interferon production
GO:0032615 interleukin-12 production
GO:0032655 regulation of interleukin-12 production
GO:0032735 positive regulation of interleukin-12 production
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0033273 response to vitamin
GO:0033590 response to cobalamin
GO:0033619 membrane protein proteolysis
GO:0034599 cellular response to oxidative stress
GO:0034612 response to tumor necrosis factor
GO:0034614 cellular response to reactive oxygen species
GO:0035094 response to nicotine
GO:0035728 response to hepatocyte growth factor
GO:0035729 cellular response to hepatocyte growth factor stimulus
GO:0035872 nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway
GO:0035994 response to muscle stretch
GO:0038061 NIK/NF-kappaB signaling
GO:0038093 Fc receptor signaling pathway
GO:0038095 Fc-epsilon receptor signaling pathway
GO:0042035 regulation of cytokine biosynthetic process
GO:0042063 gliogenesis
GO:0042089 cytokine biosynthetic process
GO:0042090 interleukin-12 biosynthetic process
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042176 regulation of protein catabolic process
GO:0042177 negative regulation of protein catabolic process
GO:0042303 molting cycle
GO:0042493 response to drug
GO:0042542 response to hydrogen peroxide
GO:0042633 hair cycle
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043200 response to amino acid
GO:0043278 response to morphine
GO:0043279 response to alkaloid
GO:0043434 response to peptide hormone
GO:0043588 skin development
GO:0045075 regulation of interleukin-12 biosynthetic process
GO:0045084 positive regulation of interleukin-12 biosynthetic process
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045685 regulation of glial cell differentiation
GO:0045687 positive regulation of glial cell differentiation
GO:0046626 regulation of insulin receptor signaling pathway
GO:0046627 negative regulation of insulin receptor signaling pathway
GO:0046683 response to organophosphorus
GO:0048545 response to steroid hormone
GO:0048732 gland development
GO:0050727 regulation of inflammatory response
GO:0050769 positive regulation of neurogenesis
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051216 cartilage development
GO:0051591 response to cAMP
GO:0051607 defense response to virus
GO:0051962 positive regulation of nervous system development
GO:0061008 hepaticobiliary system development
GO:0061035 regulation of cartilage development
GO:0061036 positive regulation of cartilage development
GO:0061448 connective tissue development
GO:0061614 pri-miRNA transcription from RNA polymerase II promoter
GO:0070301 cellular response to hydrogen peroxide
GO:0070423 nucleotide-binding oligomerization domain containing signaling pathway
GO:0070431 nucleotide-binding oligomerization domain containing 2 signaling pathway
GO:0070555 response to interleukin-1
GO:0070741 response to interleukin-6
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071312 cellular response to alkaloid
GO:0071316 cellular response to nicotine
GO:0071347 cellular response to interleukin-1
GO:0071354 cellular response to interleukin-6
GO:0071356 cellular response to tumor necrosis factor
GO:0071375 cellular response to peptide hormone stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0097191 extrinsic apoptotic signaling pathway
GO:0098542 defense response to other organism
GO:0098773 skin epidermis development
GO:1900076 regulation of cellular response to insulin stimulus
GO:1900077 negative regulation of cellular response to insulin stimulus
GO:1901222 regulation of NIK/NF-kappaB signaling
GO:1901223 negative regulation of NIK/NF-kappaB signaling
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1901654 response to ketone
GO:1902532 negative regulation of intracellular signal transduction
GO:1902893 regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1902895 positive regulation of pri-miRNA transcription from RNA polymerase II promoter
GO:1990267 response to transition metal nanoparticle
GO:2000628 regulation of miRNA metabolic process
GO:2000630 positive regulation of miRNA metabolic process
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
Molecular Function GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000980 RNA polymerase II distal enhancer sequence-specific DNA binding
GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0000983 transcription factor activity, RNA polymerase II core promoter sequence-specific
GO:0000987 core promoter proximal region sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001078 transcriptional repressor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001158 enhancer sequence-specific DNA binding
GO:0001159 core promoter proximal region DNA binding
GO:0001205 transcriptional activator activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0003682 chromatin binding
GO:0003705 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding
GO:0008134 transcription factor binding
GO:0031490 chromatin DNA binding
GO:0031625 ubiquitin protein ligase binding
GO:0033613 activating transcription factor binding
GO:0035326 enhancer binding
GO:0042301 phosphate ion binding
GO:0042805 actinin binding
GO:0042826 histone deacetylase binding
GO:0043168 anion binding
GO:0043566 structure-specific DNA binding
GO:0044389 ubiquitin-like protein ligase binding
GO:0046982 protein heterodimerization activity
GO:0047485 protein N-terminus binding
GO:0051059 NF-kappaB binding
GO:0070491 repressing transcription factor binding
GO:0071532 ankyrin repeat binding
Cellular Component GO:0000785 chromatin
GO:0000790 nuclear chromatin
GO:0005667 transcription factor complex
GO:0033256 I-kappaB/NF-kappaB complex
GO:0044454 nuclear chromosome part
GO:0071159 NF-kappaB complex
> KEGG and Reactome Pathway
 
KEGG hsa04010 MAPK signaling pathway
hsa04014 Ras signaling pathway
hsa04024 cAMP signaling pathway
hsa04062 Chemokine signaling pathway
hsa04064 NF-kappa B signaling pathway
hsa04066 HIF-1 signaling pathway
hsa04071 Sphingolipid signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04210 Apoptosis
hsa04380 Osteoclast differentiation
hsa04620 Toll-like receptor signaling pathway
hsa04621 NOD-like receptor signaling pathway
hsa04622 RIG-I-like receptor signaling pathway
hsa04623 Cytosolic DNA-sensing pathway
hsa04660 T cell receptor signaling pathway
hsa04662 B cell receptor signaling pathway
hsa04668 TNF signaling pathway
hsa04722 Neurotrophin signaling pathway
hsa04917 Prolactin signaling pathway
hsa04920 Adipocytokine signaling pathway
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-1169091: Activation of NF-kappaB in B cells
R-HSA-1280218: Adaptive Immune System
R-HSA-5621481: C-type lectin receptors (CLRs)
R-HSA-5621575: CD209 (DC-SIGN) signaling
R-HSA-5607764: CLEC7A (Dectin-1) signaling
R-HSA-5660668: CLEC7A/inflammasome pathway
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1834949: Cytosolic sensors of pathogen-associated DNA
R-HSA-3134963: DEx/H-box helicases activate type I IFN and inflammatory cytokines production
R-HSA-5607761: Dectin-1 mediated noncanonical NF-kB signaling
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-5602358: Diseases associated with the TLR signaling cascade
R-HSA-5260271: Diseases of Immune System
R-HSA-202424: Downstream TCR signaling
R-HSA-1168372: Downstream signaling events of B Cell Receptor (BCR)
R-HSA-2871837: FCERI mediated NF-kB activation
R-HSA-2454202: Fc epsilon receptor (FCERI) signaling
R-HSA-5603027: IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
R-HSA-5603029: IkBA variant leads to EDA-ID
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-448706: Interleukin-1 processing
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-166058: MyD88
R-HSA-209560: NF-kB is activated and signals survival
R-HSA-3214841: PKMTs methylate histone lysines
R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
R-HSA-1810476: RIP-mediated NFkB activation via ZBP1
R-HSA-193692: Regulated proteolysis of p75NTR
R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP)
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
R-HSA-983705: Signaling by the B Cell Receptor (BCR)
R-HSA-166520: Signalling by NGF
R-HSA-445989: TAK1 activates NFkB by phosphorylation and activation of IKKs complex
R-HSA-202403: TCR signaling
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-933542: TRAF6 mediated NF-kB activation
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-381340: Transcriptional regulation of white adipocyte differentiation
R-HSA-1606322: ZBP1(DAI) mediated induction of type I IFNs
R-HSA-193704: p75 NTR receptor-mediated signalling
R-HSA-193639: p75NTR signals via NF-kB
Summary
SymbolRELA
Namev-rel avian reticuloendotheliosis viral oncogene homolog A
Aliases NFKB3; nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; NF-kappa-B p65delta3; NF-kappa- ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between RELA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between RELA and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29872577Lung CarcinomaInhibit immunityNF-κB RelA renders tumor-associated macrophages resistant to and capable of directly suppressing CD8+ T cells for tumor promotion. It induces B7x expression in TAMs directly, and restricts IL-10 expression indirectly by repressing expression of the NF-κB cofactor Bcl3 and subsequent Bcl3/NF-κB1-mediated transcription of IL-10. It also renders TAMs resistant to CTLs by up-regulating anti-apoptotic genes.
Summary
SymbolRELA
Namev-rel avian reticuloendotheliosis viral oncogene homolog A
Aliases NFKB3; nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; NF-kappa-B p65delta3; NF-kappa- ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of RELA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -3.45; FDR: 0.00124 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.51; FDR: 0.04110 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolRELA
Namev-rel avian reticuloendotheliosis viral oncogene homolog A
Aliases NFKB3; nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; NF-kappa-B p65delta3; NF-kappa- ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of RELA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4090.0728
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.420.861
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4050.812
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2810.47
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.030.989
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6070.835
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0930.8
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1730.916
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0040.998
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6790.7
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0210.698
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0230.583
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of RELA in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolRELA
Namev-rel avian reticuloendotheliosis viral oncogene homolog A
Aliases NFKB3; nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; NF-kappa-B p65delta3; NF-kappa- ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RELA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolRELA
Namev-rel avian reticuloendotheliosis viral oncogene homolog A
Aliases NFKB3; nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; NF-kappa-B p65delta3; NF-kappa- ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RELA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RELA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolRELA
Namev-rel avian reticuloendotheliosis viral oncogene homolog A
Aliases NFKB3; nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; NF-kappa-B p65delta3; NF-kappa- ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RELA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolRELA
Namev-rel avian reticuloendotheliosis viral oncogene homolog A
Aliases NFKB3; nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; NF-kappa-B p65delta3; NF-kappa- ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of RELA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolRELA
Namev-rel avian reticuloendotheliosis viral oncogene homolog A
Aliases NFKB3; nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; NF-kappa-B p65delta3; NF-kappa- ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between RELA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolRELA
Namev-rel avian reticuloendotheliosis viral oncogene homolog A
Aliases NFKB3; nuclear factor of kappa light polypeptide gene enhancer in B-cells 3; NF-kappa-B p65delta3; NF-kappa- ......
Chromosomal Location11q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting RELA collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting RELA.
ID Name Drug Type Targets #Targets
DB08908Dimethyl fumarateSmall MoleculeKEAP1, RELA2